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Introduction
Women with early-stage breast cancer generally have a 
favorable prognosis after ﬁ  rst-line treatment and surgical 
resection. Adding adjuvant therapy, especially for patients 
at high risk of recurrence, has been shown to improve 
outcomes, although such therapies may be associated 
with deteriorations in bone health [1]. When disease 
does recur in these patients, it is typically not at the 
primary tumor site but rather from cancer stem cells 
(CSCs) that metastasize to distant sites, such as the bone 
marrow [2]. In these sites, interactions between the CSCs 
and the normal tissue can create niches that facilitate 
cancer cell dormancy, allowing the CSCs to evade the 
cyto  toxic or proapoptotic eﬀ  ects of therapies while main-
taining their capacity to seed future metastases [3,4].
Fortunately, the multistep process required for cancer 
metastasis (for example, cancer cell mobilization, 
invasion into the vasculature, extravasation at distant 
sites, and angiogenesis) aﬀ  ords many opportunities for 
therapeutic intervention. Recent evidence has revealed 
that bisphosphonates, which have been investigated for 
protecting bone health in women receiving adjuvant 
therapy for breast cancer, can also have clinically 
meaningful anticancer eﬀ  ects. In the present article we 
review the available data indicating that bisphosphonates 
can reduce disease recurrence and can maintain bone 
health in women with breast cancer receiving adjuvant 
therapy.
Bone metastases and the bone marrow 
microenvironment
Bone is a common site for tumor metastasis, and some 
primary cancers appear to have an especially high 
propensity for metastasis to bone [5]. For example, the 
majority of patients with metastatic breast cancer or 
prostate cancer (approximately 75%) and a substantial 
proportion of patients with metastatic lung cancer (30 to 
40%) will develop bone metastases [5]. Th   e tendency of 
cancer cells to metastasize to bone is probably the end 
result of several factors including vascular pathways, the 
highly vascular nature of bone marrow (which increases 
the probability that cancer cells will be deposited in bone 
marrow capillaries), and molecular characteristics of the 
cancer cells that allow them to adapt to the bone marrow 
microenvironment [3,4,6]. In fact, breast cancer cells 
have been shown to adopt an osteoblast-like phenotype 
that may help them survive in the bone marrow [7]. Once 
in the bone marrow, CSCs may remain dormant for 
prolonged periods of time; however, the speciﬁ  c signals 
that control CSC dormancy and reactivation are 
currently not well understood [3].
Several distinct niches in the bone marrow allow CSCs 
to interact with osteoblasts (endosteal niche) and 
hemato  poietic stem cells (vascular niche), and these 
niches can shelter CSCs from adjuvant therapies [4]. 
Contact with integrins and exposure to bone-derived 
cytokines in the bone marrow can reduce proapoptotic 
signaling, and cell-adhesion molecules bind to receptors 
on cancer cells and promote drug resistance [3]. Dormant 
CSCs in the bone marrow (often referred to as 
disseminated tumor cells) are thought to be the source 
for distant metastasis to secondary sites, and may be 
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derived growth factors. Indeed, a strong correlation 
between disseminated tumor cells in bone marrow or 
circulating CSCs in the bloodstream and an increased 
risk of disease recurrence (distant and locoregional) has 
been demonstrated in several studies [8-10]. In addition, 
many chemotherapy and endocrine therapy regimens 
increase bone turnover and release of growth factors, 
supporting CSC growth in the bone. Chemotherapy 
could therefore both lead to the death of and facilitate the 
survival (through dormancy in the bone marrow) of 
cancer cells.
Preventing bone metastases with bone-targeted 
therapies
Th   e goal of adjuvant therapy for early-stage breast cancer 
is to reduce the risk of disease recurrence by targeting 
residual CSCs in the blood, regional lymph nodes, bone 
marrow, and ipsilateral and contralateral breast tissue. 
For most patients with endocrine-responsive breast 
cancer, surgical resection followed by adjuvant endocrine 
therapy produces excellent outcomes, and the risk of 
relapse is low. Th  is approach may fall short in some 
women, however, primarily because quiescent CSCs in 
the bone marrow are resistant to cytotoxic chemotherapy 
or other targeted adjuvant therapies that are eﬀ  ective 
only against actively cycling cancer cells. For example, 
adjuvant endocrine therapy eﬀ   ectively reduces the 
proliferation of breast cancer cells by reducing circulating 
estrogen to barely detectable levels, or by blocking the 
action of estrogen (that is, tamoxifen). Reducing estrogen 
levels also increases bone turnover, however, which may 
render the bone marrow environment more conducive to 
the survival of CSCs. As a result, adjuvant therapies that 
target the microenvironment in addition to the CSCs 
may indirectly aﬀ   ect the ability of dormant cells to 
survive and reactivate, and therefore could be more 
successful.
Th  ere is growing interest in using agents such as 
bisphosphonates to target CSCs in the bone micro-
environment. Because bisphosphonates inhibit osteoclast-
mediated bone resorption, they reduce the release of 
bone-derived growth factors and other modulators 
necessary to promote cancer cell growth, diﬀ  erentiation, 
and tumor formation in bone. For example, the 
bisphosphonate zoledronic acid (ZOL) was shown in 
preclinical assays to prevent mesenchymal stem cells 
from secreting factors (RANTES and IL-6) involved in 
breast cancer migration and proliferation [11]. Adding 
ZOL also sensitizes colon CSCs to γδ T-cell-mediated 
cytotoxicity [12]. In addition, data from multiple clinical 
trials suggest that bone-targeted therapy not only renders 
the bone a less hospitable environment, but may also 
directly aﬀ   ect the viability of CSCs. Recently, clinical 
trials in women with breast cancer suggested that bis-
phosphonates can improve outcomes by targeting both 
the seed (the CSCs) and the soil (the bone marrow micro-
environment) [13-15]. Indeed, ZOL was shown to reduce 
disseminated tumor cells in four phase II trials in women 
with breast cancer (total n = 435) [16-21]. In addition, 
investigational therapies – such as receptor activator of 
NF-κB ligand inhibitors, Src inhibitors, cathepsin K 
inhibitors, and integrin inhibitors – may render the bone 
microenvironment less favorable for cancer cell growth; 
however, their eﬃ   cacy has not been established clinically. 
Th   e unique potential of bisphosphonates to prevent bone 
metastases may be that they have both direct and indirect 
anticancer activity (targeting the cancer cells and bone).
Bisphosphonate adjuvant clinical trials
Th  e potential anticancer activity of adjuvant bisphos-
phonate therapy for reducing disease recurrence has 
been examined in several clinical trials in women with 
early-stage breast cancer. Data from two clinical trials 
(n  =  1,359) indicated that patients who received oral 
clodronate (1,600 mg/day for 2 years) experienced a delay 
in developing bone metastases and showed improved 
disease-free survival and overall survival [22,23]. 
Conversely, another trial (n = 299) of oral clodronate 
(1,600 mg/day for 3 years) found no signiﬁ  cant survival 
beneﬁ   t; however, imbalances in the clodronate and 
control groups may have contributed to the lack of 
anticancer eﬀ  ect in this trial [24,25]. Although two out of 
the three trials showed a beneﬁ   t with adjuvant 
clodronate, a meta-analysis of data from breast cancer 
trials was unable to detect a signiﬁ  cant overall survival 
beneﬁ   t or a signiﬁ   cant reduction in bone metastases 
(Figure 1) [23,24,26,27]. Data from a trial in patients 
receiving adjuvant chemotherapy for breast cancer 
(n = 953) suggested that oral pamidronate (150 mg twice 
daily for 4 years) does not improve disease outcomes in 
patients in this setting [28]. Oral pamidronate may not, 
however, be as eﬃ   cacious as the approved intravenous 
formulation.
Although trials of oral bisphosphonates (clodronate 
and pamidronate) have produced variable results, recent 
clinical trials of intravenous ZOL have demonstrated 
somewhat more consistent anticancer beneﬁ   ts in the 
adjuvant setting. In the ABCSG-12 trial (n = 1,803), 
premenopausal women with endocrine-responsive breast 
cancer received goserelin and were randomized to 
tamoxifen or anastrozole, with or without ZOL (4 mg 
every 6 months) [15]. After a median follow-up of 
48 months, ZOL signiﬁ  cantly reduced the risk of disease-
free survival events by 36% (hazard ratio = 0.64; P = 0.01) 
(Figure 2) [14,15,29], and produced a trend toward 
improved overall survival compared with patients who 
received endocrine therapy without ZOL. Overall, adding 
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locoregional, contralateral, and distant recurrences (at 
bone and nonbone sites). At 62 months’ median follow-
up, more than 2 years after treatment ended, ZOL 
continued to reduce the risk of disease-free survival 
events by 32% (hazard ratio = 0.68; P = 0.009), with 
similar risk reductions in each of the endocrine therapy 
arms (Figure 2) [14,15,29]. Similar anticancer eﬀ  ects of 
ZOL were also observed in a trial in postmenopausal 
women with early breast cancer receiving adjuvant endo-
crine therapy. Among women enrolled in the ZO-FAST 
study (n = 1,065), patients who received upfront ZOL had 
fewer disease recurrence events at all sites, and ZOL 
reduced the relative risk of disease-free survival events by 
41% (hazard ratio = 0.59; P = 0.0314) compared with 
patients in the delayed-ZOL group at 36  months 
(Figure 2) [14,15,29].
In addition to the anticancer eﬀ   ects observed in 
adjuvant breast cancer trials, an exploratory analysis of 
patients with stage II/III breast cancer who received 
neoadjuvant therapy with or without ZOL (n = 205) in 
the AZURE trial (total n = 3,360) found that ZOL had 
anticancer eﬀ   ects on the primary tumor [13]. In this 
substudy, ZOL reduced residual invasive tumor size by 
44% (15.5 mm vs. 27.4 mm for chemotherapy alone; 
P = 0.006) and improved complete pathologic response 
nearly twofold in patients who received ZOL combined 
with neoadjuvant chemotherapy compared with neo-
adjuvant chemotherapy alone.
Additional data on the potential anticancer beneﬁ  ts of 
antiresorptive agents have emerged from the benign 
osteoporosis setting. In three recent large database 
studies (total n = 164,718), healthy postmenopausal 
women receiving oral bisphosphonates to treat osteo-
porosis were found to have a signiﬁ  cantly reduced risk of 
breast cancer compared with women who did not receive 
bisphosphonates, an eﬀ  ect that appeared to persist even 
after indirectly compensating for likely diﬀ  erences  in 
bone mineral density between users and nonusers of 
bisphosphonates [30-32]. Th  ese data support the anti-
cancer beneﬁ  ts of bisphosphonates observed in women 
receiving adjuvant breast cancer therapy, and suggest 
that the anticancer beneﬁ  ts of bisphosphonate therapy 
may be clinically meaningful even early in the disease 
course, before the cancer has reached a detectable level.
Taken together, these data are intriguing and suggest 
that bisphosphonates can have anticancer eﬀ  ects on the 
primary tumor and on disseminated CSCs. Several 
ongoing clinical trials of bisphosphonates in the 
neoadjuvant and adjuvant settings will further deﬁ  ne the 
eﬃ   cacy of these agents in the breast cancer setting.
Maintaining bone health in women with early 
breast cancer
It is well understood that many therapies for women with 
early-stage breast cancer can have negative eﬀ  ects on 
bone and may result in signiﬁ  cant bone loss – that is, low 
bone mineral density (BMD) – within the ﬁ   rst 1 to 
2 years of therapy. In premenopausal women, cytotoxic 
chemotherapy can induce premature menopause and, in 
women with hormone-responsive breast cancer, ovarian 
suppression and endocrine therapy can cause rapid bone 
loss [33,34]. Similarly, adjuvant aromatase inhibitor 
therapy is associated with signiﬁ   cant bone loss and 
increased fracture risk in postmenopausal women 
compared with women who received tamoxifen [35-38]. 
At diagnosis, women with breast cancer may already have 
several additional risk factors, unrelated to bone loss 
from breast cancer therapies, which add to their fracture 
risk. Th   ese baseline risk factors may include age 
(>65 years), a history of fragility fracture after the age of 
50, body mass index <20 kg/m2, family history of osteo-
porosis, current or history of smoking, and oral 
corticosteroid use >6 months [1]. Each of these risk 
factors has been shown to increase a woman’s fracture 
risk independent of BMD and is important in deter-
mining her overall fracture risk. Th  e bone health of 
women with early breast cancer is often under assault by 
Figure 1. Meta-analysis of adjuvant clodronate trials in women 
with early breast cancer. (a) Forest plot of overall survival in early 
breast cancer patients receiving adjuvant clodronate therapy. 
(b) Forest plot of bone-metastasis-free survival in early breast cancer 
patients receiving adjuvant clodronate therapy. Data from Diel and 
colleagues [26], Saarto and colleagues [24], and Powles and colleagues 
[23]. Reprinted by permission from Macmillan Publishers Ltd: Figures 1 
and 2 from [27], © 2007 [www.nature.com/bjc/index.html].
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proactively address these risks through a combination of 
diet and lifestyle changes, as well as through pharma-
ceutical intervention when needed.
Several recent clinical trials examined the use of 
bisphosphonates to prevent bone loss associated with 
adjuvant endocrine therapy in premenopausal and post-
menopausal women with early-stage breast cancer. 
Results from early trials of oral bisphosphonates 
demonstrated that these agents have only limited eﬃ   cacy 
for preventing cancer treatment-induced bone loss and 
may be associated with poor patient compliance for 
treatment regimens outside the clinical trial setting. In 
the recent small-scale ARIBON study in patients (n = 50) 
with early breast cancer and osteopenia receiving 
anastrozole (1  mg/day), however, monthly oral iban-
dronate (150 mg) improved lumbar spine BMD compared 
with baseline by approxi  mately 3% after 1 and 2 years of 
therapy [39]. In two other studies in post  meno  pausal 
women receiving anastrozole (1 mg/day) for preven  tion 
(n  =  59) or for treatment (n  =  118) of endocrine-
responsive breast cancer, weekly oral risedro  nate 
improved lumbar spine and/or hip BMD compared with 
baseline [40,41]. Additionally, the SABRE trial showed 
that oral risedronate (35  mg/week) inhibited lumbar 
spine and total hip BMD loss for up to 24  months of 
treatment in postmenopausal women with a moderate to 
high risk of fragility fracture receiving anastrozole 
(1 mg/day) [42].
Intravenous bisphosphonates (for example, ZOL) can 
also prevent bone loss associated with adjuvant endo-
crine therapy in premenopausal and post  meno  pausal 
women. In the ABCSG-12 trial bone substudy (n = 404) 
in premenopausal women, adding ZOL maintained stable 
BMD during 3 years of endocrine therapy, and increased 
BMD for at least 2 years after treatment completion [43]. 
In four similarly designed trials (total n = 2,240), upfront 
ZOL (4 mg every 6 months) signiﬁ  cantly increased BMD 
in postmeno  pausal women during adjuvant letrozole 
therapy com  pared with baseline [14,44-46]. Across all 
studies, the overall percentage diﬀ  erence in BMD between 
the upfront-ZOL and delayed-ZOL groups continued to 
increase for up to 5 years [47]. Although these studies 
were not powered to detect between-group diﬀ  erences in 
fracture incidence, fewer fractures occurred in women 
who received upfront ZOL.
Current oncology guidelines for addressing bone health 
in women receiving adjuvant endocrine therapy for early 
breast cancer rely mainly on BMD T scores to determine 
the fracture risk and to guide treatment. Th  e American 
Society of Clinical Oncology guidelines published in 2003 
rely on BMD as an indicator, and only recommend anti-
resorptive therapy with bisphosphonates in women who 
are osteoporotic [48]. Recently updated osteoporosis 
guidelines from the World Health Organization and the 
National Osteoporosis Foundation use BMD in addition 
to risk factors as indicators (family history of hip fracture; 
personal history of fracture, rheumatoid arthritis, or 
secondary osteoporosis; glucocorticoid use; smoking; 
alcohol intake) to decide when to initiate bisphosphonate 
therapy. Although the recently developed FRAX 
algorithm (used by the World Health Organization and 
the National Osteoporosis Foundation) can estimate 
fracture risk in healthy postmenopausal women, it is not 
appropriate for women with breast cancer because it 
does not adequately assess the fracture risk associated 
Figure 2. Relative risk of disease recurrence in two clinical trials of adjuvant zoledronic acid. Forest plot of disease-free survival in the 
ABCSG-12 trial in premenopausal women with early breast cancer and in the ZO-FAST study in postmenopausal women with early breast cancer. 
Horizontal lines, 95% confi  dence intervals. ZOL, zoledronic acid. Data from Gnant and colleagues [15,29] and Eidtmann and colleagues [14].
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may not be routinely available for breast cancer patients.
As the importance of clinical risk factors for fracture 
has become increasingly apparent, emerging guidance 
from oncology experts has evolved to include an overall 
fracture risk assessment using clinical risk factors and 
BMD when available. For example, experts from the UK 
recommend using risk factors, age, and BMD to 
determine whom to treat [49]. Similarly, a group from 
Belgium recommends using speciﬁ   c risk factors for 
osteo  porotic fractures (age, prior fragility fracture, 
medication use, or disease or medical condition that is 
associated with low bone mass or bone loss) to assess 
fracture risk [50]. Finally, an international panel of 
experts recommends using identiﬁ  ed risk factors (T score 
<1.5, age >65 years, body mass index <20 kg/m2, family 
history of hip fracture, personal history of fragility 
fracture after age 50, oral corticosteroid use >6 months, 
and smoking) with or without BMD (Figure 3) [1]. 
Although the details of the algorithms used to assess 
fracture risk in women with breast cancer vary slightly 
between expert groups, the overall consensus seems to 
favor a comprehensive fracture risk evaluation to 
deter  mine who should receive antiresorptive therapy. 
Combining aromatase inhibitor therapy with bisphos-
phonate treatment in women with a high risk of fracture 
also appears to perhaps allow patients to gain the 
anticancer beneﬁ  t of aromatase inhibitor therapy without 
the negative eﬀ  ects on bone health.
Conclusions
Th   e available evidence clearly indicates that bone health 
is an important consideration when initiating therapy for 
women with early breast cancer. Recent clinical guide-
lines have improved identiﬁ  cation of patients who would 
beneﬁ   t from adjuvant bisphosphonate therapy in this 
setting. In addition to observed beneﬁ  cial  eﬀ  ects  on 
BMD, recent data suggest there is also a potential for 
disease recurrence advantages with bisphosphonates. 
Based on the anticancer activity of bisphosphonates for 
reducing disease recurrence in the adjuvant breast cancer 
setting, as well as the provocative ﬁ   nding of reduced 
breast cancer incidence in the osteoporosis trials, there is 
increasing evidence that beginning bisphosphonate 
therapy early in the disease course may provide the 
greatest beneﬁ  ts.
Figure 3. Recommended management strategy for patients with breast cancer receiving aromatase inhibitor therapy. Recommendations 
based on results from trials in breast cancer patients and healthy populations. The largest body of evidence for treatment of aromatase inhibitor 
(AI)-associated bone loss is for zoledronic acid (4 mg every 6 months). aIf patients experience an annual decrease in bone mineral density (BMD) 
≥5% (using the same dual-energy X-ray absorptiometry machine), secondary causes of bone loss such as vitamin D defi  ciency should be evaluated 
and bisphosphonate therapy considered. Use the lowest T score from three sites. BMI, body mass index. Reprinted from [1] with permission from 
the European Society for Medical Oncology.
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